Company / Gross Profit
ADMA Biologics, Inc. Gross Profit History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Gross Profit
$292.8M
FY2025
5-year range
$1.2M / $292.8M
FY2021-FY2025
Trend
+33.3%
vs FY2024
Sector context
#19 of 29
Health Care
What the data says
At $293M, ADMA Biologics, Inc.'s gross profit ranks #19 of 29 in the Health Care sector. Gross Profit has increased for 6 consecutive years, from -$25M in FY2018 to $293M in FY2025.
Based on SEC 10-K filings.
$293M in FY2025 with a 3-year CAGR of +529.6%.
Improved from $89M to $293M over the past 2 years.
Health Care sector context is included.
Gross Profit over time
Growth rates
- 3-Year CAGR
- +529.6%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#19 of 29 in Health CareTop 66% of 29This company $292.8M Sector average $3.5B
▼
-91.5% below sector average
Key checks
Key Insights
- ADMA Biologics, Inc.'s gross profit has grown for 5 consecutive years.
- 3-year CAGR of +529.6%, indicating consistent growth.
- In FY2025, gross profit increased 33.3% year-over-year.
- Ranks #19 out of 29 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 3.37 (safe zone, above 2.9 threshold)
- Strong profit margin: 46.4%
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Gross ProfitValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $292.8M | +33.3% |
| FY2024 | $219.6M | +146.8% |
| FY2023 | $88.9M | +7480.6% |
| FY2022 | $1.2M | +0.0% |
| FY2021 | $1.2M | +106.2% |
| FY2020 | -$19.1M | - |
| FY2019 | - | - |
| FY2018 | -$25.2M | -686.2% |
| FY2017 | $4.3M | +0.0% |
| FY2016 | $4.3M | +97.9% |
As of FY2025 · SEC 10-K · Updated Jul 1, 2026